Standardized assessments of binding, neutralization, ADCC, and ADCVl effector activities of antibodies elicited by candidate HlV-1 Env immunogens are critical for informing HIV-1 vaccine design. Core B (Immune Monitoring Core) will provide standardized and validated GCLP humoral immune monitoring assay services for evaluating antibody responses elicited by Ad26/Ad26 and A26/MVA vector regimens with and without an Env gp140 trimer protein boost. We further propose to utilize additional assays for mapping the epitope specificities of NAb generated by these unique vaccine regimens. These services will provide critical support for Projects 1 and 2 by providing data that will help guide immunogen design and strategies for vaccine formulation and delivery.! We propose the following Specific Aims for Core B: 1. We will assess Env-specific antibody responses in subjects immunized with candidate HlV-1 Env immunogens for binding, neutralization, ADCC, and ADCVl effector activities. 2. We will utilize multiple assay formats for mapping the epitope specificities of antibodies elicited by vaccine regimens tested in Projects 1 and 2.

Public Health Relevance

The development of a preventative HlV-1 vaccine that can generate protective immunity remains a great scientific challenge. As novel Env immunogens enter preclinical and clinical testing', it is critical that optimized and validated in vitro assays are used to perform standardized measurements of vaccine-elicited antibody responses.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-EC-A)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beth Israel Deaconess Medical Center
United States
Zip Code
Stephenson, Kathryn E; Neubauer, George H; Reimer, Ulf et al. (2015) Quantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine development. J Immunol Methods 416:105-23
Baden, Lindsey R; Liu, Jinyan; Li, Hualin et al. (2015) Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans. J Infect Dis 211:518-28
Barouch, Dan H; Picker, Louis J (2014) Novel vaccine vectors for HIV-1. Nat Rev Microbiol 12:765-71
Dugast, Anne-Sophie; Chan, Ying; Hoffner, Michelle et al. (2014) Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies. PLoS One 9:e97229
Balandya, Emmanuel; Miller, Andrew D; Beck, Matthew et al. (2014) Adenovirus serotype 26 and 35 vectors induce simian immunodeficiency virus-specific T lymphocyte responses in foreskin in rhesus monkeys. J Virol 88:3756-65
Barouch, Dan H; Michael, Nelson L (2014) Accelerating HIV-1 Vaccine Efficacy Trials. Cell 159:969-72
Penaloza-MacMaster, Pablo; Teigler, Jeffrey E; Obeng, Rebecca C et al. (2014) Augmented replicative capacity of the boosting antigen improves the protective efficacy of heterologous prime-boost vaccine regimens. J Virol 88:6243-54
Nkolola, Joseph P; Bricault, Christine A; Cheung, Ann et al. (2014) Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer. J Virol 88:9538-52
Baden, Lindsey R; Walsh, Stephen R; Seaman, Michael S et al. (2014) First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002). J Infect Dis 210:1052-61
Whitney, James B; Hill, Alison L; Sanisetty, Srisowmya et al. (2014) Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512:74-7

Showing the most recent 10 out of 26 publications